---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001987"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T01:09:34.124690+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2 for neuropathic pain

## Summary
- Phase 1 trial of oral ketamine analog Ketamir-2 for neuropathic pain; 56 healthy volunteers in SAD/MAD cohorts.
- Preclinical data showed superior efficacy vs. pregabalin and gabapentin in validated neuropathic pain models.
- Study completion expected Q4 2025; Phase 2a in diabetic neuropathic pain to start by year-end 2025.
- First human efficacy data anticipated in first half of 2026.

## SEC filing metadata
- accession: 0001641172-25-001987
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225001987/0001641172-25-001987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225001987/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001987
- JSON: https://secwatch.observer/filing/0001641172-25-001987.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.